Overview

Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)

Status:
Terminated

Trial end date:
2011-11-09

Target enrollment:

Participant gender:

Summary

multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE

Phase:

Phase 4

Details

Lead Sponsor:

Cubist Pharmaceuticals LLC

Treatments:

Daptomycin
Gentamicins